Clinical Trial Update: A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2) [Phase 1]

View source ↗

Summary

Phase I, open-label, multicenter study to evaluate safety, tolerability, cellular kinetics, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD012…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• AZD0120

Snippet

Sponsor: AstraZeneca | Conditions: Multiple Myeloma | Phase 1 | Status: RECRUITING